Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine
Tabbo F.;Novello S.
2020-01-01
Abstract
Next-generation ALK TKIs have become the new standard of care in first-line setting in advanced ALK-positive NSCLC patients. However, sequential strategies at progression are relevant, as may have an impact on patients’ outcome. In this commentary we discuss whether genomic-tailored strategies at progression would be more suitable for improving outcome of ALK-positive NSCLC patients.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
558.22 kB
Formato
Adobe PDF
|
558.22 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
